Company: SRPT
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0000950170-25-058003
Chunk: 69

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 69
---
     | 562,885 |
| Deirdre Connelly           |     | $          |  19,418 |     | $         | 356,216 |     | $         | 355,341 |     | —            |     | $     | 730,975 |

(1) The amounts in the “Stock Awards” and “Option Awards” columns reflect the aggregate grant date fair value of RSU and option awards granted in 2024 calculated in accordance with FASB ASC Topic 718, disregarding the effect of forfeitures. Assumptions used in the calculation of these amounts are included in Note 15 to the consolidated financial statements set forth in our Annual Report. As of December 31, 2024, each of our non-employee directors had 3,679 shares underlying options and 1,846 shares underlying RSUs outstanding except for Deirdre Connelly who was appointed to the Board in September 2024 and had 6,442 shares underlying options and 2,842 shares underlying RSUs outstanding. THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

<div align='center'>43</div>

EXECUTIVE CO MPENSATION Compensation Discus sion and Analysis Introdu ction The Compensation Discussion and Analysis (CD&A) that follows is organized in three parts: I. 2024 Compensation Program Overview and Factors That Influenced 2024 Named Executive Officers' Compensation II. 2024 Named Executive Officer Compensation III. Compensation Agreements for Named Executive Officers Throughout this CD&A, individuals who served as our principal executive officer and principal financial officer during 2024, as well as the other executive officers listed in the Summary Compensation Table included herein, are referred to as the “named executive officers.” Our named executive officers for 2024 were:

| Name                        |     | Position(s)                                                                    |
| Douglas S. Ingram           |     | President and Chief Executive Officer                                          |
| Ian M. Estepan              |     | Executive Vice President, Chief Financial Officer                              |
| Bilal Arif                  |     | Executive Vice President, Chief Technical Operations Officer                   |
| Louise Rodino-Klapac, Ph.D. |     | Executive Vice President, Head of R&D, Chief Scientific Officer                |
| Dallan Murray(1)            |     | Executive Vice President, Chief Customer Officer                               |
| Ryan E. Brown(2)            |     | Former Executive Vice President, Chief General Counsel and Corporate Secretary |